A retrospective observational study of CAR T-cell therapy outcomes-Experience from MSE Foundation Trust
British Journal of Haematology
; 201(Supplement 1):122, 2023.
Article
in English
| EMBASE | ID: covidwho-20240824
ABSTRACT
The most common non-Hodgkin's lymphoma (NHL) is diffuse large B-cell lymphoma (DLBCL), an aggressive lymphoma that can be cured with standard frontline chemo-immunotherapy in 60%-70% of patients but with historically poor outcomes for relapsed/refractory disease. Patients with relapsed DLBCL after autologous stem cell transplant (ASCT) or with chemotherapy-refractory disease have a particularly dismal prognosis, with a median overall survival (OS) of only 6 months. Chimeric antigen receptor (CAR) T-cell therapy has significantly improved outcomes for patients with relapsed/refractory large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma, with multiple FDA approved CAR T products now commercially available in many developed world including European countries. Ongoing studies seek to move CAR T cells to earlier lines of therapy and to characterise the efficacy and safety of CAR T-cell approaches in additional lymphoma histologies including relapsed/refractory follicular lymphoma and chronic lymphocytic leukaemias. Other areas of active research address CAR T in combination with other lymphoma-directed therapies, and mechanisms of CAR T resistance. We conducted a retrospective observational study assessing the outcomes of patients referred to our tertiary centre, University College London hospital NHS foundation Trust (UCLH) from January 2018 to December 2022, over a 48-month period. We collected data including patients' demographics, types of lymphomas, prior lines of therapies including stem cell transplantation, bridging therapies as appropriate, complications and overall response rate. We also analysed the communication between teams during the challenging period of the COVID-19 pandemic.
adult; bridging therapy; cancer patient; cancer recurrence; cancer resistance; chimeric antigen receptor T-cell; chimeric antigen receptor T-cell immunotherapy; chronic lymphatic leukemia; clinical assessment; complication; conference abstract; coronavirus disease 2019; demographics; drug safety; England; female; follicular lymphoma; histology; histopathology; human; human cell; line of treatment; male; observational study; outcome assessment; overall response rate; pandemic; retrospective study; stem cell transplantation; surgery; trust; chimeric antigen receptor; endogenous compound
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Observational study
/
Prognostic study
Language:
English
Journal:
British Journal of Haematology
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS